MetLife (NYSE:MET) posts better-than-expected sales in Q3 2026

MetLife (MET) reported Q3 2026 revenue of $20.52B, up 14.6% YoY and beating estimates by 3.5%. EPS of $2.78 was in line with expectations. Net premiums missed estimates, and shares remained flat post-earnings. Book value per share grew 35.6% YoY to $59.41, but missed estimates by 0.6%.

Original reporting
Published Nov 4, 2026, 9:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MetLife (NYSE:MET) posts better-than-expected sales in Q3 2026 — source image
Decision brief

The 30-second read

$METNeutralMed
01

Why it matters

The mixed results suggest limited immediate price movement; investors will watch guidance and premium trends for future direction.

02

Market read

First‑time earnings disclosure for a large‑cap insurer; relevance driven by revenue beat and premium miss.

03

What to watch

Potential impact of rising interest rates on investment income and upcoming regulatory changes for insurers were not discussed.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

MetLife's Q3 2026 earnings were released, showing a revenue beat but mixed operating metrics.

Company-level read

Ticker impact

$METNeutralMedium confidence
Context

MetLife reported Q3 2026 revenue of $20.52B, beating estimates by 3.5% while EPS was in line, marking the first public release of these results.

Expected impact

likely modest upward pressure as the market prices in the revenue beat, but limited upside due to in‑line EPS

Evidence & confidence

Large‑cap insurer with a revenue surprise; investors typically react positively to top‑line beats, yet earnings were flat, suggesting a balanced reaction.

Market effects

Insurance sector may see slight re‑rating as revenue growth outpaces peers, but premium miss highlights competitive pressure.

U.S. financials could experience modest gains in pre‑market trading.

Limited; impact confined to U.S. insurers and broader financials.

Counterpoint

Investors might view the premium miss and flat EPS as a sign of underlying weakness, prompting a short bias despite the revenue beat.

Key entities

  • MetLife

    Global insurer reporting Q3 2026 results.

Related articles

$METHighAI 8/10

MetLife Q3 Earnings Call Highlights

MetLife reported Q3 earnings, with variable investment income of $1.5B for the first nine months, on track to exceed its $1.6B full-year guidance. Group Benefits and Retirement adjusted earnings rose 14% and 12% respectively. International operations saw mixed results, with Asia up 21% and Latin America down 5%. The company repurchased $650M in shares in Q3 and is on track to meet its full-year targets.

$METMedAI 8/10

Chesnara bags £1.7bn MetLife UK closed life book in latest takeover

Chesnara agreed to acquire MetLife UK's closed-book life insurance business for £1.7bn in assets, subject to regulatory approval. The deal is expected to generate £90m in lifetime cashflows, with £45m added to Own Funds and Contractual Service Margin. Chesnara aims to strengthen its UK business and future cash generation. Analysts note the deal boosts long-term capital generation without significantly impacting Chesnara's acquisition firepower.

$METMed

Chesnara To Buy MetLife's Closed-book UK Life Insurance Firm; Terms Not Disclosed

Chesnara plc (CSN.L) agreed to buy MetLife's (MET) closed-book UK life insurance unit, MetLife UK Limited, for an undisclosed sum. The deal, expected to close in early 2027, will add 18,000 policies and £1.7 billion in assets. Chesnara anticipates £45 million boost to Own Funds and Contractual Service Margin, with £90 million in lifetime cash flows, half within five years. Shares rose 1.15%.

$METHighAI 9/10

MetLife (MET) Q3 2026 Earnings Call Transcript

MetLife (MET) reported Q3 2026 adjusted earnings of $1.8B ($2.85 EPS), up 17% YoY. Adjusted EPS ex-items rose 22%, with ROE at 19.6%. Growth was driven by Group Benefits, Retirement & Income Solutions, and Asia. The company repurchased $650M in shares, bringing YTD capital return to $3.5B.